reviewTop 1% cited
Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis
American Journal of Kidney Diseases · 2007 · Vol. 49(2) · pp. 186–193
Xiaolei Zhu✉(National Cancer Institute)Shenhong Wu(Yale University)William L. Dahut(National Cancer Institute)Chirag R. Parikh(VA Connecticut Healthcare System)
Cancer Treatment and PharmacologyAngiogenesis and VEGF in CancerChemotherapy-induced cardiotoxicity and mitigationBevacizumabMedicineProteinuriaInternal medicineOncologyRelative riskMeta-analysisVascular endothelial growth factorRisk factorConfidence interval
MeSH terms
BevacizumabAntibodies, MonoclonalHumansHypertensionProteinuriaRisk FactorsVascular Endothelial Growth Factor AAntibodies, Monoclonal, Humanized
Citations
623
FWCI
22.36
field-weighted impact
References
31
Percentile
100%
vs. same field & year
Citations per year
Cited by
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
Hypertension · 2018 · 1,036 citations
References
Quantitative Synthesis in Systematic Reviews
Annals of Internal Medicine · 1997 · 2,490 citations
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Endocrine Reviews · 2004 · 3,664 citations
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Journal of Clinical Oncology · 2004 · 1,949 citations
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
New England Journal of Medicine · 2004 · 10,930 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.